ICON PLC (ICLR)

Currency in USD
166.05
+1.54(+0.94%)
Closed·
167.64+1.59(+0.96%)
·
ICLR is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
163.80167.70
52 wk Range
66.57203.91
Key Statistics
Prev. Close
166.05
Open
163.8
Day's Range
163.8-167.7
52 wk Range
66.57-203.91
Volume
516.57K
Average Volume (3m)
986.01K
1-Year Change
3.9697%
Book Value / Share
122.43
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ICLR Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
185.56
Upside
+11.75%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

ICON PLC News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

10 Buy
6 Hold
1 Sell
Ratings:
17 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 185.56
(+11.75% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Baird
Buy194.00+16.83%192.00MaintainJul 31, 2026
Truist Securities
Buy209.00+25.87%207.00MaintainJul 31, 2026
Citi
Hold165.00-0.63%-New CoverageJul 30, 2026
Baird
Buy192.00+15.63%186.00MaintainJul 13, 2026
Truist Securities
Buy207.00+24.66%159.00UpgradeJun 30, 2026

ICON PLC SWOT Analysis


CRO Market Dynamics
Explore ICON's navigation of industry challenges, including bookings volatility and demand uncertainties in the competitive CRO landscape
Financial Resilience
Delve into ICON's solid financial health, with EPS forecasts of $13.40 (FY1) and $14.06 (FY2), despite recent market pressures
Strategic Positioning
Learn how ICON leverages proprietary technology and global scale to capture high-quality opportunities in a shifting pharmaceutical landscape
Valuation Insights
Analysts set price targets ranging from $155 to $263, suggesting potential for value realization as transient headwinds subside
Read full SWOT analysis

ICON PLC Earnings Call Summary for Q2/2026

  • ICON posted Q2 2026 adjusted EPS of $2.56 on revenue of $2.06B, beating estimates, but shares fell 1.08% premarket to $176.25.
  • Adjusted EBITDA margin dropped to 15.9% from 20.5% YoY due to higher pass-through activity that boosted revenue but pressured profitability.
  • Strong bookings continued with $3.7B in gross wins and a 1.51x net book-to-bill ratio, marking third consecutive quarter of industry-leading performance.
  • Management reaffirmed full-year 2026 guidance, expecting revenue near high end of range but lower margins if elevated pass-through activity persists.
  • Share repurchases to resume in Q3; management emphasized focus on EBITDA dollar growth and sequential improvement over margin percentages.
Last Updated: 07/30/2026, 09:14 PM
Read Full Transcript

Earnings

Latest Release
Jul 29, 2026
EPS / Forecast
2.56 / 2.55
Revenue / Forecast
2.06B / 2B
EPS Revisions
Last 90 days

ICLR Income Statement

Compare ICLR to Peers and Sector

Metrics to compare
ICLR
Peers
Sector
Relationship
P/E Ratio
473.7x26.3x−0.4x
PEG Ratio
−4.92−1.300.00
Price/Book
1.4x2.7x2.6x
Price / LTM Sales
1.5x2.6x3.1x
Upside (Analyst Target)
12.3%13.7%48.2%
Fair Value Upside
Unlock7.3%5.8%Unlock

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, contract staffing, data solutions, and laboratory services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers testing services comprising bioanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, medical imaging, real world intelligence, site and patient, and strategic solutions. Additionally, it provides therapeutics for cardiovascular, central nervous system, endocrine and metabolic disorders, hepatology, infectious diseases, internal medicine immunology, and oncology. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
43.04M55.78%7.15B
Other Institutional Investors
41.45M44.22%6.88B
Public Companies & Retail Investors
0.000.00%0.00
Total
84.49M100.00%14.03B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Artisan Partners Limited Partnership10.73%8,278,9451,374,719
Artisan Partners Funds, Inc. - Artisan International Value Fund8.20%6,323,1351,049,957

People Also Watch

138.74
SPCX
+4.23%
74.83
ZTS
+2.99%
813.51
LITE
-8.61%
990.85
GEV
+0.05%
66.57
CNC
+1.22%

FAQ

What Is the ICON PLC (ICLR) Stock Price Today?

The ICON PLC stock price today is 166.05 USD.

What Stock Exchange Does ICON PLC Trade On?

ICON PLC is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for ICON PLC?

The stock symbol for ICON PLC is "ICLR."

What Is the ICON PLC Market Cap?

As of today, ICON PLC market cap is 12.81B USD.

What Is ICON PLC's Earnings Per Share (TTM)?

The ICON PLC EPS (TTM) is 0.35.

When Is the Next ICON PLC Earnings Date?

ICON PLC will release its next earnings report on Oct 28, 2026.

From a Technical Analysis Perspective, Is ICLR a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has ICON PLC Stock Split?

ICON PLC has split 2 times.

How Many Employees Does ICON PLC Have?

ICON PLC has 40200 employees.

What is the current trading status of ICON PLC (ICLR)?

As of Aug 11, 2026, ICON PLC (ICLR) is trading at a price of 166.05 USD, with a previous close of 166.05 USD. The stock has fluctuated within a day range of 163.80 USD to 167.70 USD, while its 52-week range spans from 66.57 USD to 203.91 USD.

What Is ICON PLC (ICLR) Price Target According to Analysts?

The average 12-month price target for ICON PLC is 185.56 USD, with a high estimate of 220 USD and a low estimate of 155 USD. 10 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +11.75% Upside potential.

What Is the ICLR After Hours Price?

ICLR's last after hours stock price is 167.64 USD, the stock has decreased by 1.59, or 0.96%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.